DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* INTEGRAGEN *


 

2000 - IDF
Évry
(near Paris)
www.integragen.com

 

Discovery, Diagnostics
Key words: Genes, Genomic mutations, Diabetes, Obesity, Bipolar disorders, Schizophrenia, Autism, GenomeHIP
Mission: to research in gene targets and to market molecular diagnostics products and services that provide clinicians with new tools of personalized diagnosis, treatment, and therapy
Clients: Prescribers
business@integragen.com

Age: 16 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Courtieu (Bernard) [born 1964, Vet.D., MBA, ex-Gemini Conseil, Ariba]
Sc.Dir.-CSO: Liebaert (François) [MBA, ex-Schering, Abbott]
Fin.Dir.-CFO: Riot-Lamotte (Laurence) [CESEM, ex-Aureus-Pharma, Deloitte & Touche, Thomson, Deutsche Telekom France]
SalesMktg: Martin (Emmanuel) [Pharm.D., ex-Applied Biosystems]
BusDev: Brady (David) [MBA, ex-Biogen-Idec, Lonza]
Financers (Hist.): CDC Innovation, GenAvent, Bioam, Bay Tech, AGF P.E., Société Générale A.M., DSM

Turnover (M€) : 2.81 (2009), 2.26 (2008), 0.53 (2006)
Total funding (M€) : 23.0
Last funding (M€) : 6.7
Focus : Cardiovasc
Position : Launch
Company confirm : none

 

History
DATEMILESTONETYPETIME
2012 .07 Round-financing : 2.0 M€ (reserved private new shares) with fund A Plus Finance RFIN [12 years]
2012 .04 Launch of ARISk test in USA, a genetic tool to evaluate risk of autism MKTG [11 years]
2012 .03 Research : launch of a study on 600 autist children to confirm the predictive value of genetic markers in identification of disease, at Cleveland Clinic (Ohio, USA) R&D [11 years]
2011 .04 Licensing-in of technology with Johns Hopkins University and Massachusetts General Hospital regarding autism diagnostic test ARISk LICIN [10 years]
2010 .10 Set-up of US subsidiary in Cambridge (Massachussetts) ORGC [10 years]
2010 .06 Listing on Alternext Paris : 6.7 M€ PBO [9 years]
2010 .04 Research : positive results on combined analysis of several options in a genetic score to identify individuals with high risks of developing autisme R&D [9 years]
2010 .02 Licensing-out to Transgenomic to develop and distribute its genetic test of autisme in USA LICOUT [9 years]
2010 .01 Licensing-in of technology to set-up a service lab in genetic analysis and a demo lab in Europe, from Fluidigm (USA) LICIN [9 years]
2009 .06 Partnering research agreement with Servier for genotyping applications in Servier's Genese clinical trial R&D [8 years]
2007 .09 Nomination : Bernard Courtieu as CEO, replacing Jan Mous ORGN [7 years]
2006 .12 Set-up of US subsidiary (operations) in New York State ORGC [6 years]
2006 .11 3rd round-financing : 2.0 M€, by Royal DSM, within a research agreement to develop molecular diagnostics RFINC [6 years]
2005 .11 2nd round-financing : 8.0 M€, by AGF P.E., Société Générale A.M., and previous shareholders RFINB [5 years]
2004 .01 Research : discovery of a human gene linked to autism R&D [3 years]
2003 .07 Nomination : Jan Mous as CEO [born 1950, Ph.D., ex-Lion Bioscience AG, as CSO, Roche], replacing Jean-Luc Gerbier ORGN [3 years]
2001 .06 1st round-financing : 6.3 M€, by CDC Innovation, GenAvent, Bioam, Bay Tech RFINA [0 year]
2000 .03 Company founded by Philippe Gesnouin (CIO), Jörg Hager, Anne Philippi, Nathalie Vionnet, Jean-Luc Gerbier [CEO, ex-BMS, Biostar], Peter Brooks, as a spin-off from CNG (Centre National du Génotypage) ORGF [0 year]

Actualisation / Updating: 14-Nov-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende